Increasing FDA approvals of biosimilars for treatment of stomach cancer is expected to drive growth of the stomach cancer drugs market
The stomach cancer drugs market revenue is expected to increase, owing to increasing number of FDA approvals for biosimilars. Adoption of biosimilars in last five years is on a high demand because of the comparatively lower price than biologics treatment of stomach cancer. For instance, in 2017 Biocon Ltd., in partnership ... Read more